Posted: February 5, 2025 at 2:42 am
WHITE PLAINS, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical technology company pioneering bio-interventional approaches for chronic eye diseases, today announced the appointment of Adam Szaronos, as its new Chief Executive Officer. Mr. Szaronos succeeds company founder and innovator Sean Ianchulev, MD, MPH who will remain as Chairman of the Board and Chief Medical Officer.
The rest is here:
Iantrek Appoints Adam Szaronos as Chief Executive Officer
Posted: February 5, 2025 at 2:42 am
Ghent, Belgium, 4th February 2025
Read more here:
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America
Posted: February 5, 2025 at 2:42 am
SportsGel will feature a sports-specific range of products available for license, with first deal to launch in China in H1 2025 SportsGel will feature a sports-specific range of products available for license, with first deal to launch in China in H1 2025
Here is the original post:
Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
Posted: February 5, 2025 at 2:42 am
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here.
Continued here:
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted: February 5, 2025 at 2:42 am
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –
Posted: February 5, 2025 at 2:42 am
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in February.
Continued here:
Allogene Therapeutics Announces Participation in February Investor Conferences
Posted: February 5, 2025 at 2:42 am
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 12:00 pm – 12:30 pm ET.
Read the original post:
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted: February 5, 2025 at 2:42 am
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company’s innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Go here to see the original:
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Posted: February 5, 2025 at 2:42 am
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.
Continued here:
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
Posted: February 5, 2025 at 2:42 am
Now available on the AISight® Platform, PathAssist Derm is an AI-assisted histopathology tool that enhances dermatopathology research workflows, accelerating skin cancer research
Continued here:
PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI
